Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure

ObjectiveThe prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) reg...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Junxia Hu, Xin Wang, Fei Chen, Mengjie Ding, Meng Dong, Wanqiu Yang, Meifeng Yin, Jingjing Wu, Lei Zhang, Xiaorui Fu, Zhenchang Sun, Ling Li, Xinhua Wang, Xin Li, Shuangshuang Guo, Dianbao Zhang, Xiaohui Lu, Qing Leng, Mingzhi Zhang, Linan Zhu, Xudong Zhang, Qingjiang Chen
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2021-06-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	decitabine chemotherapy diffuse large B cell lymphoma modified DHAP regimen safety
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2021.687374/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!